April 23, 2020 10:43 AM EDT

An upsized IPO? In this economy? Of course; Sofinnova and AbbVie lead $38M Series A for Parkinson’s startup

→ Sofinnova and AbbVie Ventures have led a $38 million Series A for Nitrome Biosciences, a biotech that is developing …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

An up­sized IPO? In this econ­o­my? Of course; Sofinno­va and Ab­b­Vie lead $38M Se­ries A for Parkin­son’s start­up